Racial disparity in estrogen receptor positive breast cancer patients receiving trimodality therapy

Wright, Jean L.; Reis, Isildinha M.; Zhao, Wei; Panoff, Joseph; Takita, Cristiane; Sujoy, Victoria; Gómez, Carmen; Jordà, Mercè; Franceschi, Dido; Hurley, Judith

doi:10.1016/j.breast.2011.11.003

Cited by 18 publications

(18 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…[26] Other large studies have shown that in those with HR positive breast cancer, survival outcomes among African Americans are significantly worse than Caucasians. [25, 32, 35] An analysis comparing the outcomes of African American with non-African Americans breast cancer patients treated on a large randomized phase III adjuvant trial, reported inferior disease free and overall survival outcomes for HR positive African Americans patients. [32] TNBC patients did not have any differences in outcome by race.…”

Section: Discussionmentioning

confidence: 99%

Differences in the mutational landscape of triple-negative breast cancer in African Americans and Caucasians

Ademuyiwa

Tao

Luo

et al. 2016

Breast Cancer Res Treat

View full text Add to dashboard Cite

Background Triple negative breast cancer (TNBC) occurs at higher frequency in African Americans compared with Caucasians. It is unclear if the biology of TNBC is different in African American versus Caucasians. In this study, we sought to evaluate racial differences in the molecular pathology of TNBC. Methods Using data from The Cancer Genome Atlas, we identified TNBC patients with information on race. We analyzed differences in clinical characteristics, tumor somatic mutations, and gene expression patterns by race from whole exome and microarray data. Results 1104 patients were identified, of which 178 had TNBC. TNBC was more frequent in African American than Caucasians (33.3% vs 14.9%). Although, more African American than Caucasians overall were classified as basal-like from PAM50 gene expression (34.8% vs 16.1%), no differences in the TNBC cohort were observed. Median tumor somatic mutation counts were higher in African American versus Caucasians (39.5 vs 34), but no racial differences in the mutation counts in TNBC were observed. Somatic mutation analysis revealed racial differences in specific high prevalence genes in all patients- [TP53: 46% in African American vs 27% in Caucasians; PIK3CA: 23% in African American vs 34% in Caucasians; and MLL3: 12% in African American vs 6% in Caucasians]. TNBC patients did not have any specific high prevalence genes associated with racial differences. There were no racial differences in gene expression patterns in selected genes involved in breast cancer biology. Overall, African Americans had shorter TTP and worse DFS. Racial differences in clinical outcomes were not observed in TNBC. Conclusion The mutational landscape of TNBC is similar between African Americans and Caucasians. The higher frequency of TNBC in African Americans is therefore not associated with a different genomic profile of common established tumor regulatory pathway genes. Other modifiable factors may exist that contribute to the racial disparity in TNBC.

show abstract

Section: Discussionmentioning

confidence: 99%

Differences in the mutational landscape of triple-negative breast cancer in African Americans and Caucasians

Ademuyiwa

Tao

Luo

et al. 2016

Breast Cancer Res Treat

View full text Add to dashboard Cite

show abstract

“…Despite recent advances in treatment and prognosis, the racial gap in breast cancer death rates has widened, 1,2 with black women having consistently lower survival rates [3][4][5][6][7] and lower disease-specific survival rates in comparison with white women 8,9 ; black women are currently 39% more likely to die of breast cancer than their white counterparts. 10 Multiple studies have reported higher mortality rates for black women at all disease stages, even after adjustments for age, tumor size, nodal status, hormone receptor status, and histology.…”

Section: Introductionmentioning

confidence: 99%

Does race predict survival for women with invasive breast cancer?

Walsh

Zabor

Stempel

et al. 2019

Cancer

View full text Add to dashboard Cite

BACKGROUND: Black women with breast cancer have lower survival rates and higher recurrence rates in comparison with white women. This study compared treatment and survival outcomes for black and white women at a highly specialized tertiary care cancer center. METHODS: An institutional review board-approved, retrospective institutional database review was performed to identify all black women treated for invasive breast cancer between 2005 and 2010. Women with a prior history of breast cancer, stage IV cancer, or bilateral breast cancer were excluded. White women had similar exclusion criteria applied and were then matched to black women 1:1 by age and diagnosis year. Clinicopathologic and treatment variables were compared by race. Kaplan-Meier methodology was used to estimate overall survival (OS) and disease-free survival (DFS); a multivariable analysis was conducted with Cox regression models. RESULTS: The study group consisted of 1332 women (666 black). The median tumor size was larger in black women (1.6 vs 1.3 cm; P < .001). Black women had more nodal disease (41.1% vs 32%; P < .001) and had tumors that were more frequently an estrogen receptor-negative (32.9% vs 15%; P < .001), progesterone receptor-negative (47.1% vs 30.2%; P < .001), or triple-negative (TN) subtype (24% vs 8.9%; P < .001) in comparison with white women. Black women also had inferior DFS and OS; race was not an independent prognostic indicator in the multivariable analysis. CONCLUSIONS: Black women had more advanced disease and adverse prognostic indicators at diagnosis, but race was not an independent predictor of outcome. Black women were significantly more likely to have TN breast cancer. Further research is necessary to understand the differences in tumor biology associated with race. Cancer 2019;125:3139-3146.

show abstract

“…For example, our findings suggest the role of the ADME gene SLC7A5, a solute carrier (SLC) transporter, in racial disparity in the tamoxifen treatment outcome of breast cancer patients -AA patients exhibited lower sensitivity to tamoxifen than did EA patients [41,42] (Supplementary Figure 7). Our BRCA dataset analysis showed that the E-CpG cg27560818 on SLC7A5 exhibited a significantly lower methylation level in the AA population than that in the EA population.…”

Section: Discussionmentioning

confidence: 88%

Interethnic DNA Methylation Difference and Its Implications in Pharmacoepigenetics

Chu

Yang

2017

Epigenomics

View full text Add to dashboard Cite

Aim: This is the first systematic study to examine the population differentiation effect of DNA methylation on the treatment response and drug absorption, distribution, metabolism and excretion in multiple tissue types and cancer types. Materials & methods: We analyzed the whole methylome and transcriptome data of primary tumor tissues of four cancer types (breast, colon, head & neck and uterine corpus) and lymphoblastoid cell lines for African and European ancestry populations. Results: Ethnicity-associated CpG sites exhibited similar methylation patterns in the two studied populations, but the patterns differed between tumor tissues and lymphoblastoid cell lines. Ethnicity-associated CpG sites may have triggered gene expression, influenced drug absorption, distribution, metabolism and excretion, and showed tumorspecific patterns of methylation and gene regulation. Conclusion: Ethnicity should be carefully accounted for in future pharmacoepigenetics research.

show abstract

Racial disparity in estrogen receptor positive breast cancer patients receiving trimodality therapy

Cited by 18 publications

References 14 publications

Differences in the mutational landscape of triple-negative breast cancer in African Americans and Caucasians

Differences in the mutational landscape of triple-negative breast cancer in African Americans and Caucasians

Does race predict survival for women with invasive breast cancer?

Interethnic DNA Methylation Difference and Its Implications in Pharmacoepigenetics

Contact Info

Product

Resources

About